# Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC

> **NCT02724332** · PHASE1 · COMPLETED · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 300 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Rapamycin

## Interventions

- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT02724332
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2016-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724332, "Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02724332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*